New shot shows promise for tough eczema in phase 3 trial
NCT ID NCT06477835
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a biologic drug called SIM0718 in 259 adults and teens with moderate to severe atopic dermatitis (eczema) that did not respond well to creams. Participants received either the drug or a placebo every two weeks for 16 weeks. The goal was to see if the drug could significantly improve skin symptoms like redness and itching.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SIM0718 (a biologic injection)
- What this could lead to
- If it works, this could offer a new treatment option for people with moderate to severe eczema that is not controlled by creams.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The drug may not work better than placebo, and side effects like infections are possible with biologics.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?